Characterizing variability in cardiovascular drug responses

British Journal of Clinical Pharmacology

Volumn 57, Issue 5, 2004, Pages 535-537

  Donnelly, Richard ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPHEDRINE; FLUINDOSTATIN; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METOPROLOL; NIFEDIPINE; PRAVASTATIN; TYRAMINE; WARFARIN;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIURESIS; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EXCRETION; DRUG RESPONSE; DRUG SCREENING; EDITORIAL; FLUSHING; GENETIC ANALYSIS; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; PATIENT; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RISK REDUCTION; TORSADE DES POINTES; TREATMENT OUTCOME;

EID: 2342511499     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02148.x     Document Type: Editorial

References (7)

1. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the rule of halves still valid? J Hum Hyperten 1997; 11: 213-20.
2. Shepherd J. Statins for primary prevention: strategic options to save lives and money. J R Soc Med 2004; 97: 66-71.
3. Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002; 144: 31-8.
4. Buhler FR, Hulthen DL, Kiowski W. The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol 1982; 4: 5350-7.
5. Robertson DRC, Waller DG, Renwick AG, George CF. Age related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 12: 401-4.
6. Roden M. Cardiovascular pharmacogenomics. Circulation 2003; 108: 3071-4.
7. Segmund W, Ludwig K, Giessmann T, et al. The effects of human MDR-1 genotypeon the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmac Ther 2002; 72: 572-83.